anti-Trop2 monoclonal antibody

Anti-Trop2 monoclonal antibodies are targeted biologics designed to bind to Trophoblast cell-surface antigen 2 (Trop2), a glycoprotein that is highly expressed in various epithelial tumors, including breast, lung, gastric, pancreatic, and colorectal cancers. Trop2 overexpression is frequently associated with increased tumor aggressiveness and poor clinical prognosis. These antibodies serve as critical components in several therapeutic modalities: they can act as standalone agents, as the targeting moiety in antibody-drug conjugates (ADCs) such as sacituzumab govitecan, or as building blocks for multi-specific antibodies. For example, they are engineered into bispecific T-cell engagers (BiTEs) by linking them to CD3-binding domains to redirect T-cell-mediated cytotoxicity specifically toward Trop2-positive malignant cells. Research often focuses on optimizing the complementarity-determining regions (CDRs) of these antibodies to balance high tumor specificity with reduced on-target off-tumor toxicity in normal epithelial tissues.

Other names

anti-Trop2 antibodyanti-Trop-2 antibodyanti-Trop 2 antibodyTrop2-directed antibodyTrop-2-directed antibodyTrop 2-directed antibodyhumanized anti-Trop2 monoclonal antibody